Dr. Marshall on the Luminary Awards in GI Cancers
November 15th 2017John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the first annual Luminary Awards in GI Cancers, which is honoring five individuals who have devoted their time, talent and resources to improving the care for patients and families affected by GI cancers.
Read More
Dr. Marshall on Molecular Variances Between Right- Versus Left-Sided Colon Cancer
January 30th 2017John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, associate director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses molecular variances between right- and left-sided colon cancer.
Read More
Dr. Marshall on Y-90 Mechanism of Action in Liver-Dominant CRC
January 5th 2017John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, discusses the mechanism of action of Yttrium-90 in the treatment of patients with liver-dominant, metastatic colorectal cancer.
Read More
Dr. Marshall on Next Steps Following Y-90 in Liver-Metastatic CRC
December 17th 2016John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the next steps following the findings from the phase III SIRFLOX trial, which explored the addition of selective internal radiation therapy (SIRT), using Y-90 resin microspheres, to FOLFOX-based first-line chemotherapy in patients with liver-dominant metastatic colorectal cancer (mCRC).
Read More
Dr. Marshall on the Safety Profile of Y-90 in Colorectal Cancer
November 29th 2016John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the safety profile of Yttrium-90, particularly when combined with capecitabine as a treatment for patients with liver-dominant metastatic colorectal cancer.
Read More
Dr. John L. Marshall on Y-90 in Colorectal Cancer
November 23rd 2016John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses Y-90 in metastatic castration resistant colorectal cancer (mCRC).
Read More
Dr. Marshall on Challenges With Cancer Moonshot Initiative
November 10th 2016John L. Marshall, MD, chief, Division of Hematology/Oncology, Georgetown University Hospital, discusses potential obstacles ahead with the Cancer Moonshot Initiative following the results of the 2016 United States presidential election.
Read More
Dr. John Marshall on Differentiating Squamous and Adenocarcinoma in GI Cancers
June 30th 2016John L. Marshall, MD, chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, clinical research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the difference between squamous and adenocarcinoma in esophageal and gastric cancer.
Read More